



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Walter Dunn, MD, PhD**

Committees: **Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee (DSaRM/PDAC)**

Meeting Date: **November 19, 2024**

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On November 19, 2024, the Committees will discuss the reevaluation of the Clozapine Risk Evaluation and Mitigation Strategy (REMS) and possible changes to minimize burden on patients, pharmacies, and prescribers while maintaining safe use of clozapine.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stocks/investments	Stock holdings in a party to the matter (b) (6) and six competing firms ((b) (6)).	Aggregate value: \$25,000 – \$75,000
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

WALTER DUNN Digitally signed by WALTER DUNN
Date: 2024.10.24 11:03:25 -07'00'

Signature

10/24/2024
Date